Work

Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning

Year: 2019

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2019-127445

Authors: Haris Ali, David Snyder, Tracy Stiller, Timothy Synold, Saloomeh Mokhtari, Joycelynne Palmer, Amandeep Salhotra, Vinod A. Pullarkat, Ji-lian Cai, Stephen J Forman, Matthew Mei, Ryotaro Nakamura

Institutions: City Of Hope National Medical Center, Kaiser Permanente

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2983690591

Cites:

Cited by: 4

Related to: 10